SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction

Jul.07.2022
SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction
The world's largest e-cigarette manufacturer, SMOORE, partners with SIAT to study nicotine addiction and reduce nicotine levels in e-cigarettes.

The world's largest electronic cigarette manufacturer, SMOORE, has announced the launch of the world's first real-time monitoring research project on nicotine addiction.


The vaporization process between e-cigarettes and combustible cigarettes is vastly different, resulting in distinct physical and chemical properties obtained from vaporization and tobacco combustion, respectively.


Electronic cigarette company, SMOORE, has partnered with the Shenzhen Institute of Advanced Technology (SIAT) to undertake a new research project aimed at exploring ways to significantly reduce the nicotine strength in electronic cigarette products and ultimately lower it to non-addictive levels.


Under the direction of Nobel laureate Dr. Erwin Neher, the Neher Laboratory for Neural Plasticity in Shenzhen is the sixth laboratory in Shenzhen named after a Nobel laureate and the first dedicated to neuroscience. The laboratory focuses on researching the human brain and aims to better understand the mechanisms behind diseases and addictions through the use of the latest advanced techniques in modern neuroscience.


This joint study will investigate the secretion and metabolism of dopamine in the brains of animals, and use the data gathered to simulate the human brain state when nicotine is consumed. The laboratory will conduct controlled experiments by exposing test subjects to aerosol environments created by FEELM vaporization and combustion of tobacco.


The project aims to reduce the nicotine intake and subsequent dependence in adult e-cigarette users. This study will also assist SMOORE's research and development team in enhancing the design of e-cigarette devices by improving efficiency through modifying heating elements and atomizers to enhance the vaping experience.


Researchers involved in the project will monitor the aerosolization of e-liquid to gain a better understanding of nicotine absorption, distribution, metabolism in the human body. Additionally, the study will investigate how nicotine is absorbed by different organs to reveal the sensory satisfaction of e-cigarettes.


Dr. Xiong Yuming, Vice President of SMOORE Shenzhen Institute of Basic Research, stated that...


The process of vaporization between electronic cigarettes and combustible cigarettes is vastly different. Therefore, the physical and chemical properties obtained from vaporization and tobacco burning are also completely different. Our study focuses on the potential mechanisms of vaporization and tobacco burning, with the aim of exploring the delivery and absorption of nicotine to reduce the impact of these products on health.


This project is being supported by Southwest University in Chongqing, China. A phased report is expected to be released in the second half of 2022, which will outline the different effects of nicotine on the brain in electronic cigarettes and combustible tobacco products. This joint study on nicotine dependency aims to put an end to global nicotine addiction. Looking towards the future, FEELM aims to provide products that do not lead to nicotine dependency by reducing nicotine levels as close to zero as possible without compromising satisfaction.


This article is a compilation of third-party information, intended for educational and informational purposes only. The copyright for the compiled information belongs to the original media and authors. If there are any copyright infringements, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives